Good work, Zander! I just came across it and as I have a directionally similar piece coming up tomorrow, I made sure to include a link.
One pushback though: Some markets will still be leanings towards scale and the median user. Pharmaceuticals, which you mention, are a good example. The necessary upfront investment in research leads to a situation where creating super-focused, longtail products not profitable. That’s why research into many rare illnesses doesn’t get proper funding.
That being said, yes, the general direction is certainly right.